NASDAQ:MDGL Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free MDGL Stock Alerts $210.98 -0.34 (-0.16%) (As of 05/14/2024 ET) Add Compare Share Share Today's Range$209.84▼$219.7650-Day Range$193.33▼$283.2352-Week Range$119.76▼$302.68Volume262,278 shsAverage Volume516,391 shsMarket Capitalization$4.50 billionP/E RatioN/ADividend YieldN/APrice Target$345.09 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Madrigal Pharmaceuticals alerts: Email Address Madrigal Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.73 Rating ScoreUpside/Downside63.6% Upside$345.09 Price TargetShort InterestBearish18.67% of Shares Sold ShortDividend StrengthN/ASustainability-0.92Upright™ Environmental ScoreNews Sentiment-0.02Based on 30 Articles This WeekInsider TradingSelling Shares$31.36 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($26.94) to ($17.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.48 out of 5 starsMedical Sector255th out of 2,771 stocksPharmaceutical Preparations Industry77th out of 1,288 stocks 4.4 Analyst's Opinion Consensus RatingMadrigal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 9 buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageMadrigal Pharmaceuticals has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Madrigal Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted18.67% of the outstanding shares of Madrigal Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMadrigal Pharmaceuticals has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Madrigal Pharmaceuticals has recently increased by 16.72%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMadrigal Pharmaceuticals does not currently pay a dividend.Dividend GrowthMadrigal Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMadrigal Pharmaceuticals has received a 73.28% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Madrigal Pharmaceuticals is -0.92. Previous Next 1.1 News and Social Media Coverage News SentimentMadrigal Pharmaceuticals has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 30 news articles for Madrigal Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 12 people have searched for MDGL on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat FollowsOnly 16 people have added Madrigal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -45% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Madrigal Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $31,362,420.00 in company stock.Percentage Held by Insiders23.92% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.50% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Madrigal Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($26.94) to ($17.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Madrigal Pharmaceuticals is -9.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Madrigal Pharmaceuticals is -9.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMadrigal Pharmaceuticals has a P/B Ratio of 10.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Madrigal Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden FINISHED On June 13th?Thanks to Biden’s disgraceful leadership we now have sky-high inflation… unchecked immigration… rampant crime… and a “woke mob” hell bent on destroying the America you and I know and love. Biden’s days are numbered.Click here now to see his shocking evidence. About Madrigal Pharmaceuticals Stock (NASDAQ:MDGL)Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.Read More MDGL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDGL Stock News HeadlinesMay 14 at 4:30 AM | americanbankingnews.comMadrigal Pharmaceuticals (NASDAQ:MDGL) PT Lowered to $200.00 at B. RileyMay 13 at 5:41 AM | americanbankingnews.comFY2028 EPS Estimates for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Decreased by AnalystMay 13 at 2:16 AM | americanbankingnews.comB. Riley Comments on Madrigal Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:MDGL)May 11 at 2:12 AM | americanbankingnews.comLeerink Partnrs Brokers Reduce Earnings Estimates for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Madrigal Pharmaceuticals Amid Strong Start for RezdiffraMay 10, 2024 | americanbankingnews.comJMP Securities Lowers Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target to $381.00May 10, 2024 | americanbankingnews.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Cut to $382.00May 10, 2024 | americanbankingnews.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Cut to $390.00May 8, 2024 | markets.businessinsider.comMadrigal Pharmaceuticals: Strong Buy Rating Amidst Rapid Growth and Strategic InitiativesMay 8, 2024 | benzinga.comSpotlight on Madrigal Pharmaceuticals: Analyzing the Surge in Options ActivityMay 8, 2024 | finance.yahoo.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2024 Earnings Call TranscriptMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Madrigal Pharmaceuticals Amid Promising Launch of First Approved NASH Treatment and Strong Market PositioningMay 8, 2024 | finance.yahoo.comMadrigal Pharmaceuticals Inc (MDGL) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...May 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Madrigal Pharmaceuticals Amid Strong Rezdiffra Launch and Solid FinancialsMay 7, 2024 | seekingalpha.comMadrigal sees ‘tremendous interest’ in new NASH drug RezdiffraMay 7, 2024 | msn.comMDGL Stock Earnings: Madrigal Pharmaceuticals Misses EPS for Q1 2024May 7, 2024 | finance.yahoo.comMadrigal Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Rezdiffra LaunchMay 7, 2024 | globenewswire.comMadrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate UpdatesMay 5, 2024 | americanbankingnews.comMadrigal Pharmaceuticals (NASDAQ:MDGL) Shares Up 8.2%May 5, 2024 | americanbankingnews.comMadrigal Pharmaceuticals (MDGL) Set to Announce Quarterly Earnings on TuesdayApril 30, 2024 | seekingalpha.comMadrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-LabelApril 28, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - MDGLApril 26, 2024 | seekingalpha.comSagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment OpportunityApril 25, 2024 | msn.comMadrigal Pharmaceuticals to Unveil First-Quarter Results, Hosts Live WebcastApril 24, 2024 | globenewswire.comMadrigal Statement on the Passing of Dr. Stephen HarrisonSee More Headlines Receive MDGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today5/14/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:MDGL CUSIP87162T20 CIK1157601 Webwww.madrigalpharma.com Phone(267) 824-2827Fax781-274-8228Employees376Year Founded2011Price Target and Rating Average Stock Price Target$345.09 High Stock Price Target$410.00 Low Stock Price Target$150.00 Potential Upside/Downside+63.6%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($23.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-373,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-128.60% Return on Assets-78.52% Debt Debt-to-Equity Ratio0.14 Current Ratio9.39 Quick Ratio9.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$20.53 per share Price / Book10.28Miscellaneous Outstanding Shares21,312,000Free Float16,214,000Market Cap$4.50 billion OptionableOptionable Beta-0.33 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Rebecca A. Taub M.D. (Age 72)Founder, Chief Medical Officer, President of Research & Development and Director Comp: $939.83kMr. Brian J. Lynch J.D. (Age 62)Senior VP & General Counsel Comp: $763.75kMr. Alex G. Howarth (Age 55)Executive Officer Comp: $757.26kMr. William J. Sibold (Age 58)CEO, President & Director Ms. Mardi C. Dier (Age 60)CFO, Principal Financial Officer, Principal Accounting Officer & Senior VP Mr. Ronald FilippoChief Information OfficerMs. Tina E. VenturaChief Investor Relations OfficerDr. Kianoush Motesharei Ph.d. (Age 54)Senior Vice President of Business & Corporate Development Mr. Clint WallaceChief Human Resources OfficerMr. Edward ChiangSenior Vice President of Clinical & Technical OperationsMore ExecutivesKey CompetitorsAlkermesNASDAQ:ALKSIonis PharmaceuticalsNASDAQ:IONSAmicus TherapeuticsNASDAQ:FOLDDicerna PharmaceuticalsNASDAQ:DRNAGeronNASDAQ:GERNView All CompetitorsInsiders & InstitutionsPropel Bio Management LLCBought 13,000 shares on 5/14/2024Ownership: 0.202%American International Group Inc.Sold 62 shares on 5/14/2024Ownership: 0.034%Pitcairn Co.Bought 1,007 shares on 5/14/2024Ownership: 0.005%EntryPoint Capital LLCBought 155 shares on 5/14/2024Ownership: 0.001%Ameritas Investment Partners Inc.Sold 56 shares on 5/13/2024Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions MDGL Stock Analysis - Frequently Asked Questions Should I buy or sell Madrigal Pharmaceuticals stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MDGL shares. View MDGL analyst ratings or view top-rated stocks. What is Madrigal Pharmaceuticals' stock price target for 2024? 11 brokerages have issued 12-month target prices for Madrigal Pharmaceuticals' stock. Their MDGL share price targets range from $150.00 to $410.00. On average, they predict the company's share price to reach $345.09 in the next year. This suggests a possible upside of 63.6% from the stock's current price. View analysts price targets for MDGL or view top-rated stocks among Wall Street analysts. How have MDGL shares performed in 2024? Madrigal Pharmaceuticals' stock was trading at $231.38 on January 1st, 2024. Since then, MDGL shares have decreased by 8.8% and is now trading at $210.98. View the best growth stocks for 2024 here. When is Madrigal Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our MDGL earnings forecast. How were Madrigal Pharmaceuticals' earnings last quarter? Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) posted its quarterly earnings data on Tuesday, May, 7th. The biopharmaceutical company reported ($7.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($6.06) by $1.32. During the same period in the previous year, the company earned ($4.23) EPS. What ETFs hold Madrigal Pharmaceuticals' stock? ETFs with the largest weight of Madrigal Pharmaceuticals (NASDAQ:MDGL) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Alger Mid Cap 40 ETF (FRTY), Tema Cardiovascular and Metabolics ETF (HRTS), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB). What other stocks do shareholders of Madrigal Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Ayala Pharmaceuticals (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild). Who are Madrigal Pharmaceuticals' major shareholders? Madrigal Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.84%), Twin Tree Management LP (0.00%), Rheos Capital Works Inc. (0.55%), AlpInvest Partners B.V. (0.50%), Lord Abbett & CO. LLC (0.46%) and Mirae Asset Global Investments Co. Ltd. (0.46%). Insiders that own company stock include Brian Joseph Lynch, Bros Advisors Lp Baker, James M Daly, Paul A Friedman, Rebecca Taub, Remy Sukhija, Richard S Levy and Robert E Waltermire. View institutional ownership trends. How do I buy shares of Madrigal Pharmaceuticals? Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MDGL) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable ProsperityThe only AI company you should be looking atBehind the MarketsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.